扩张型心肌病患者血清IL-34的表达水平及临床意义  

Expression level and clinical significance of serum IL-34 in patients with dilated cardiomyopathy

作　　者：张文才[1] 刘茜茜 程立夏 郭森 ZHANG Wen-cai;LIU Xi-xi;CHENG Li-xia;GUO Sen(Department of Cardiology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,Henan,CHINA)

机构地区：[1]郑州大学第一附属医院心血管内科,河南郑州450000

出　　处：《海南医学》2025年第8期1071-1075,共5页Hainan Medical Journal

基　　金：国家自然科学基金青年基金项目(编号:81500362)。

摘　　要：目的探讨扩张型心肌病(DCM)患者血清IL-34的表达水平和临床意义。方法前瞻性选取2021年1月至2022年10月郑州大学第一附属医院心血管内科收治的64例DCM患者(DCM组)和64例正常体检者(对照组)纳入研究。DCM组患者随访6个月,失访10例。采用ELISA法检测所有受检者血清中IL-34的表达水平,比较两组受检者的临床资料、心功能指标和血清IL-34表达水平,采用Pearson相关系数法分析血清IL-34与N末端B型利钠肽前体(NT-proBNP)、左室舒张末内径(LVEDD)和左室射血分数(LVEF)的相关性,同时比较DCM组患者治疗前后的血清IL-34表达水平。结果与对照组比较,DCM组患者的NT-proBNP表达水平明显升高,LVEDD明显扩大,LVEF明显降低,差异均有显著统计学意义(P<0.01);DCM组患者的血清IL-34表达水平为(74.32±35.90)pg/mL,明显高于对照组的(41.37±22.49)pg/mL,差异有显著统计学意义(P<0.01);血清IL-34的表达水平随着心功能分级增加而升高(P<0.01),且与NT-proBNP(r=0.434,P<0.01)和LVEDD(r=0.460,P<0.01)呈正相关,与LVEF(r=-0.582,P<0.01)呈负相关;DCM组患者治疗后的血清IL-34表达水平为(52.30±20.75)pg/mL,明显低于DCM治疗前的(68.56±28.39)pg/mL,且治疗后患者NT-proBNP表达水平明显降低,LVEDD明显缩小,LVEF明显增加,差异均有显著统计学意义(P<0.01)。结论IL-34与扩张型心肌病患者心功能密切相关,且治疗后明显降低,提示IL-34可能成为DCM患者心功能和治疗效果评价的新指标。Objective To investigate the expression level and clinical significance of serum IL-34 in patients with dilated cardiomyopathy(DCM).Methods A total of 64 DCM patients(DCM group)and 64 normal physical ex-amination patients(control group)admitted to the Department of Cardiovascular Medicine,the First Affiliated Hospital of Zhengzhou University from January 2021 to October 2022 were prospectively selected as the study subjects.The pa-tients in DCM group was followed up for 6 months,with 10 cases lost to follow-up.The expression level of serum IL-34 in all subjects was measured using the ELISA method.Clinical data,cardiac function indicators,and serum IL-34 levels were compared between the two groups.Pearson correlation analysis was used to assess the relationship between serum IL-34 and N-terminal pro-B-type natriuretic peptide(NT-proBNP),left ventricular end-diastolic diameter(LVEDD),and left ventricular ejection fraction(LVEF).Additionally,serum IL-34 levels were compared before and after treatment in the DCM group.Results Compared with the control group,the DCM group showed significantly higher NT-proBNP levels,enlarged LVEDD,and reduced LVEF,with statistically significant differences(P<0.01).The serum IL-34 level in the DCM group was(74.32±35.90)pg/mL,significantly higher than(41.37±22.49)pg/mL in the control group(P<0.01).The expression level of serum IL-34 increased with the severity of heart function classification(P<0.01)and was positively correlated with NT-proBNP(r=0.434,P<0.01)and LVEDD(r=0.460,P<0.01),but negatively correlated with LVEF(r=-0.582,P<0.01).After treatment,the serum IL-34 level in the DCM group decreased to(52.30±20.75)pg/mL,significantly lower than the pre-treatment level of(68.56±28.39)pg/mL.Additionally,post-treatment NT-proBNP levels de-creased,LVEDD reduced,and LVEF improved,with statistically significant differences(P<0.01).Conclusion IL-34 is close-ly related to cardiac function in patients with dilated cardiomyopathy and significantly decreases after treatment,suggesting that IL-

关 键 词：扩张型心肌病 白细胞介素-34 N末端B型利钠肽前体 心功能 相关性 

分 类 号：R542.2[医药卫生—心血管疾病]